Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

885 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, Wöhrmann A, Katlama C, Wilkin T, Haubrich R, Cohen C, Farthing C, Jayaweera D, Markowitz M, Ruane P, Spinosa-Guzman S, Lefebvre E; POWER 1 and 2 study groups. Clotet B, et al. Among authors: lazzarin a. Lancet. 2007 Apr 7;369(9568):1169-78. doi: 10.1016/S0140-6736(07)60497-8. Lancet. 2007. PMID: 17416261 Clinical Trial.
A controlled trial of zidovudine in primary human immunodeficiency virus infection.
Kinloch-De Loës S, Hirschel BJ, Hoen B, Cooper DA, Tindall B, Carr A, Saurat JH, Clumeck N, Lazzarin A, Mathiesen L, et al. Kinloch-De Loës S, et al. Among authors: lazzarin a. N Engl J Med. 1995 Aug 17;333(7):408-13. doi: 10.1056/NEJM199508173330702. N Engl J Med. 1995. PMID: 7616989 Free article. Clinical Trial.
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M; TORO 2 Study Group. Lazzarin A, et al. N Engl J Med. 2003 May 29;348(22):2186-95. doi: 10.1056/NEJMoa035211. N Engl J Med. 2003. PMID: 12773645 Free article. Clinical Trial.
Virological rebound after suppression on highly active antiretroviral therapy.
Mocroft A, Ruiz L, Reiss P, Ledergerber B, Katlama C, Lazzarin A, Goebel FD, Phillips AN, Clotet B, Lundgren JD; EuroSIDA study group. Mocroft A, et al. Among authors: lazzarin a. AIDS. 2003 Aug 15;17(12):1741-51. doi: 10.1097/00002030-200308150-00003. AIDS. 2003. PMID: 12891060
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT; APRICOT Study Group. Torriani FJ, et al. Among authors: lazzarin a. N Engl J Med. 2004 Jul 29;351(5):438-50. doi: 10.1056/NEJMoa040842. N Engl J Med. 2004. PMID: 15282351 Free article. Clinical Trial.
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Nelson M, Arastéh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ Jr, Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP. Nelson M, et al. Among authors: lazzarin a. J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):404-12. doi: 10.1097/01.qai.0000185314.56556.c3. J Acquir Immune Defic Syndr. 2005. PMID: 16280694 Clinical Trial.
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.
Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arastéh K, Delfraissy JF, Stellbrink HJ, Lange J, Kuritzkes D, Eron JJ Jr, Cohen C, Kinchelow T, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Bourdeau L, Natale C, Hughes F, Chung J, Guimaraes D, Drobnes C, Bader-Weder S, Demasi R, Smiley L, Salgo MP. Trottier B, et al. Among authors: lazzarin a. J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):413-21. doi: 10.1097/01.qai.0000185313.48933.2c. J Acquir Immune Defic Syndr. 2005. PMID: 16280695 Clinical Trial.
885 results